-
Potential Safety Signal: Rhabdomyolysis May Be Linked To Onglyza, Nesina, Januvia, And Other Diabetes Drugs
FDA Was Already Investigating The Dipeptidyl Peptidase IV (DPP-IV) Inhibitor Class Of Diabetes Drugs For Kidney Or Renal Failure (Posted by Tom Lamb at DrugInjuryWatch.com) According to a new FDA quarterly report,…
-
Rate Of Gastrointestinal Bleeding Requiring Hospital Readmission Higher With Pradaxa Use Than Warfarin Use
Rehospitalization Within 30 Days For Serious Bleeding Events Reported With 13% Of Pradaxa Patients Compared To 5% Of Warfarin Patients (Posted by Tom Lamb at DrugInjuryWatch.com) Medical researchers recently reviewed population-wide electronic…
-
Will Ocaliva Get Black-Box Warning For Liver Injury Side Effects After September 2017 FDA Report?
19 Patients Have Died While Using This New Liver Disease Drug, Some When Prescribed Higher-Than-Recommended Doses (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: “FDA adds Boxed Warning to highlight correct dosing of Ocaliva…
-
A “Dear Doctor” Letter For Invokana Amputations Side Effect Was Sent September 2017 By Janssen In Canada
In US There Was A “Black-Box Warning” Added On Revised Drug Label Issued In July 2017 But Without Any Such Letter, It Seems (Posted by Tom Lamb at DrugInjuryWatch.com) The “FDA Drug…
-
Breast Implant Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL): New Medical Journal Article About Treatments
At Same Time, The American Society For Aesthetic Plastic Surgery Seems To Downplay The Significance Of This Apparent Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com) Breast implant associated anaplastic large-cell lymphoma…
